Stock Screener
Stock Research
Market Indexes
Precious Metals
Energy
Commodities
Interest Rates
Economy
Global Metrics

BridgeBio Pharma Market Cap 2018-2024 | BBIO

BridgeBio Pharma market cap history and chart from 2018 to 2024. Market capitalization (or market value) is the most commonly used method of measuring the size of a publicly traded company and is calculated by multiplying the current stock price by the number of shares outstanding. BridgeBio Pharma market cap as of April 25, 2025 is $6.43B.
  
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $6.430B $0.222B
BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United States.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $15.477B 5.66
Dr Reddy's Laboratories (RDY) India $11.411B 21.77
Bausch Health Cos (BHC) Canada $1.876B 1.36
Supernus Pharmaceuticals (SUPN) United States $1.717B 16.02
Amphastar Pharmaceuticals (AMPH) United States $1.109B 6.71
Personalis (PSNL) United States $0.282B 0.00
Taysha Gene Therapies (TSHA) United States $0.254B 0.00
Assembly Biosciences (ASMB) United States $0.075B 0.00
Sol-Gel Technologies (SLGL) Israel $0.015B 0.00
Evoke Pharma (EVOK) United States $0.003B 0.00
Teligent (TLGT) United States $0.000B 0.00